Literature DB >> 7572963

Risk factors for human immunodeficiency virus seroconversion among out-of-treatment drug injectors in high and low seroprevalence cities. The National AIDS Research Consortium.

S R Friedman1, B Jose, S Deren, D C Des Jarlais, A Neaigus.   

Abstract

From 1988 to 1991, 6,882 drug injectors in 15 US cities were interviewed and had serum samples collected. The interviews and samples were analyzed for determination of significant predictors of human immunodeficiency virus (HIV) seroconversion in the 10 low seroprevalence cities and the five high seroprevalence cities. The unit of analysis was the period of observation between consecutive paired interviews/blood samples. In Cox proportional hazards regression, significant predictors of seroconversion in the low seroprevalence cities were: not being in drug treatment, injecting in outdoor settings or abandoned buildings, using crack cocaine weekly or more frequently, engaging in woman-to-woman sex, being of non-Latino race/ethnicity, and city seroprevalence. Predictors in high seroprevalence cities were: injecting with potentially infected syringes, not being in drug treatment, and having a sex partner who injected drugs. These findings suggest that HIV may be concentrated in sociobehavioral pockets of infection in low seroprevalence cities. For reducing HIV transmission, these results suggest: 1) in low seroprevalence cities, localized monitoring to detect specific emerging sociobehavioral pockets of infection, and quick implementation of appropriate targeted interventions if necessary; 2) in high seroprevalence cities, relatively more emphasis on locality-wide outreach and syringe-exchange projects to reduce risky behavior; and 3) in both types of cities, considerable expansion of drug treatment programs.

Entities:  

Mesh:

Year:  1995        PMID: 7572963     DOI: 10.1093/oxfordjournals.aje.a117726

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  45 in total

1.  HIV incidence among injection drug users in New York City, 1992-1997: evidence for a declining epidemic.

Authors:  D C Des Jarlais; M Marmor; P Friedmann; S Titus; E Aviles; S Deren; L Torian; D Glebatis; C Murrill; E Monterroso; S R Friedman
Journal:  Am J Public Health       Date:  2000-03       Impact factor: 9.308

2.  Changes in HIV seroprevalence and related behaviors among male injection drug users who do and do not have sex with men: New York City, 1990-1999.

Authors:  Carey B Maslow; Samuel R Friedman; Theresa E Perlis; Russell Rockwell; Don C Des Jarlais
Journal:  Am J Public Health       Date:  2002-03       Impact factor: 9.308

Review 3.  Social networks, risk-potential networks, health, and disease.

Authors:  S R Friedman; S Aral
Journal:  J Urban Health       Date:  2001-09       Impact factor: 3.671

4.  Laws prohibiting over-the-counter syringe sales to injection drug users: relations to population density, HIV prevalence, and HIV incidence.

Authors:  S R Friedman; T Perlis; D C Des Jarlais
Journal:  Am J Public Health       Date:  2001-05       Impact factor: 9.308

5.  Sociometric risk networks and risk for HIV infection.

Authors:  S R Friedman; A Neaigus; B Jose; R Curtis; M Goldstein; G Ildefonso; R B Rothenberg; D C Des Jarlais
Journal:  Am J Public Health       Date:  1997-08       Impact factor: 9.308

6.  Sex-specific determinants of HIV infection among injection drug users in Montreal.

Authors:  J Bruneau; F Lamothe; J Soto; N Lachance; J Vincelette; A Vassal; E L Franco
Journal:  CMAJ       Date:  2001-03-20       Impact factor: 8.262

7.  HIV prevalence, risk behaviors, and high-risk sexual and injection networks among young women injectors who have sex with women.

Authors:  Samuel R Friedman; Danielle C Ompad; Carey Maslow; Rebecca Young; Patricia Case; Sharon M Hudson; Theresa Diaz; Edward Morse; Susan Bailey; Don C Des Jarlais; Theresa Perlis; Amber Hollibaugh; Richard S Garfein
Journal:  Am J Public Health       Date:  2003-06       Impact factor: 9.308

8.  Explaining the geographical variation of HIV among injection drug users in the United States.

Authors:  D Ciccarone; P Bourgois
Journal:  Subst Use Misuse       Date:  2003-12       Impact factor: 2.164

Review 9.  HIV prevention among injection drug users: the need for integrated models.

Authors:  David S Metzger; Helen Navaline
Journal:  J Urban Health       Date:  2003-12       Impact factor: 3.671

Review 10.  Addressing the "risk environment" for injection drug users: the mysterious case of the missing cop.

Authors:  Scott Burris; Kim M Blankenship; Martin Donoghoe; Susan Sherman; Jon S Vernick; Patricia Case; Zita Lazzarini; Stephen Koester
Journal:  Milbank Q       Date:  2004       Impact factor: 4.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.